# Propanc Biopharma, Inc.: overview PPCB · Nasdaq · CIK 1517681 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/ppcb.md) · [Financials](/companies/ppcb/financials.md) · [Filings](/companies/ppcb/filings.md) · [Insiders](/companies/ppcb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(35.97)](/filings/0001493152-25-023213.md) | [(32.23)](/filings/0001493152-26-007052.md) | [(12.50)](/filings/0001493152-26-023210.md) | not reported | [(0.39)](/filings/0001493152-25-023213.md) | [(0.30)](/filings/0001493152-26-007052.md) | [(0.28)](/filings/0001493152-26-023210.md) | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(1,942)](/filings/0001493152-25-023213.md) | [(1,001) d](/filings/0001493152-26-007052.md) | [(1,143) d](/filings/0001493152-26-023210.md) | [(1,602) d](/filings/0001493152-26-044373.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(49.23)](/filings/0001493152-23-034632.md) | [(1.80)](/filings/0001493152-24-038815.md) | [(1420.53)](/filings/0001493152-25-016069.md) | [(371.22)](/filings/0001493152-26-044373.md) | [(17.62)](/filings/0001493152-26-044373.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(5,688)](/filings/0001493152-26-044373.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ppcb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $38.3k | 25,550 | | New +25,550 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $18.1k | 12,090 | | New +12,090 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $15 | 10,242 | | New +10,242 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $3 | 2 | | New +2 | ## Recent filings [All 438 filings](/companies/ppcb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 17:00 ET | [8-K](/filings/0001493152-26-049298.md) | 3.01 Delisting notice | 0001493152-26-049298 | | 2026-10-05 | 17:15 ET | [S-1](/filings/0001493152-26-045770.md) | Registration statement | 0001493152-26-045770 | | 2026-09-25 | 17:08 ET | [10-K](/filings/0001493152-26-044373.md) | Annual report, period 2026-06-30 | 0001493152-26-044373 | | 2026-07-17 | 17:30 ET | [S-1](/filings/0001493152-26-033807.md) | Registration statement | 0001493152-26-033807 | | 2026-07-14 | 16:01 ET | [8-K](/filings/0001493152-26-033173.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-033173 | | 2026-05-14 | 17:30 ET | [10-Q](/filings/0001493152-26-023210.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023210 | | 2026-04-10 | 17:29 ET | [S-1](/filings/0001493152-26-016228.md) | Registration statement | 0001493152-26-016228 | | 2026-02-26 | 17:19 ET | [8-K](/filings/0001493152-26-008196.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-008196 | | 2026-02-19 | 17:28 ET | [S-1/A](/filings/0001493152-26-007492.md) | Registration statement, amended | 0001493152-26-007492 | | 2026-02-17 | 14:54 ET | [10-Q](/filings/0001493152-26-007052.md) | Quarterly report, period 2025-12-31 | 0001493152-26-007052 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001493152-26-044373.md), filed Sep 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1517681 - Tickers: PPCB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:01 ET. No prices; not investment advice.